Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: May 29, 2012
Last updated: July 9, 2015
Last verified: July 2015

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT).

The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute DVT in routine clinical practice.

Condition Intervention
Deep Vein Thrombosis
Venous Thrombosis
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Standard of care

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE)

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Major bleedings defined as overt bleeding associated with: A fall in hemoglobin of ≥2 g/dL; or a transfusion of ≥2 units of packed red blood cells or whole blood; or occurrence at a critical site [ Time Frame: after approximately 2 years or 30 days after stop of therapy ] [ Designated as safety issue: Yes ]
  • Number of patients with symptomatic recurrent venous thromboembolic events [ Time Frame: after approximately 2 years or 30 days after stop of therapy ] [ Designated as safety issue: Yes ]
  • All cause mortality [ Time Frame: after approximately 2 years or 30 days after stop of therapy ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Safety variables will be summarized using descriptive statistics based on adverse cardiac events collection [ Time Frame: after approximately 2 years or 30 days after stop of therapy ] [ Designated as safety issue: Yes ]
  • Number of patients with other symptomatic thromboembolic events [ Time Frame: after approximately 2 years or 30 days after stop of therapy ] [ Designated as safety issue: Yes ]
  • Treatment satisfaction (patient reported outcomes) [ Time Frame: after approximately 2 years or 30 days after stop of therapy ] [ Designated as safety issue: No ]

Enrollment: 5145
Study Start Date: June 2012
Study Completion Date: July 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Rivaroxaban (Xarelto, BAY59-7939)
Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
Group 2 Drug: Standard of care
Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
In- and outpatients in sites participating in the study

Inclusion Criteria:

  • Female and male patients
  • Patients >= 18 years
  • Patiebts with diagnosis of acute DVT and who have an indication for anticoagulation therapy for at least 12 weeks, who are willing to participate in this study and are available for follow-up

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01619007

  Show 21 Study Locations
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bayer Identifier: NCT01619007     History of Changes
Other Study ID Numbers: 15915  XA1102 
Study First Received: May 29, 2012
Last Updated: July 9, 2015
Health Authority: Austria: Federal Office for Safety in Health Care Austria: Austrian Medicines and Medical Device Agency
Austria: Ethikkommission
Canada: Ethics Review Committee
Germany: Ethics Commission
Germany: Federal Institute for Drugs and Medical Devices
Denmark: Danish Medicines Agency
Denmark: Danish Dataprotection Agency
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
France: Conseil National de l'Ordre des Médecins
Greece: National Organization of Medicines
Italy: Ethics Committee
Moldova: Medicines Agency
Norway: Norwegian Medicines Agency
Norway: Norwegian Social Science Data Services
Norway: Regional Ethics Commitee
Switzerland: Swissmedic
Switzerland: Ethikkommission
Sweden: Regional Ethical Review Board
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Spain: Comité Ético de Investigación Clínica
Hungary: Scientific and Medical Research Council Ethics Committee
Belgium: Ethics Committee
Czech Republic: State Institute for Drug Control
Israel: Ethics Commission
Netherlands: Independent Ethics Committee
Netherlands: Medical Ethics Review Committee (METC)
Slovenia: Agency for Medicinal Products - Ministry of Health
Slovenia: Ethics Committee
Portugal: National Pharmacy and Medicines Institute
Ukraine: Ethics Committee
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: National Health Service
United Kingdom: Research Ethics Committee

Keywords provided by Bayer:
Treatment of Venous Thromboembolism
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases

Additional relevant MeSH terms:
Venous Thromboembolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants processed this record on January 17, 2017